GlassScriptPhysician profile
Alpa Patel
NPI 1720110661
$9,530.93
in general payments reported to CMS, 2019-2025
52 companies · $42.06 in 2025
The $42.06 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,234 · 2022: $2,777 · 2023: $3,379 · 2024: $1,098 · 2025: $42.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,420 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,420.32 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $740.22 | 2021-2024 | Tagrisso, Lynparza, Enhertu |
| Pfizer INC. | $722.25 | 2021-2024 | |
| Celgene Corporation | $591.97 | 2021-2024 | Reblozyl, Pomalyst, Opdualag |
| Merck Sharp & Dohme LLC | $526.95 | 2021-2024 | Keytruda, Reblozyl, Welireg |
| Exelixis INC. | $492.00 | 2021-2024 | Cabometyx |
| Pharmacyclics LLC, An Abbvie Company | $469.07 | 2021-2023 | Imbruvica, Epkinly |
| Abbvie INC. | $466.47 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $457.20 | 2021-2023 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $414.58 | 2021-2024 | Tecvayli, Darzalex, Imbruvica |
| Novartis Pharmaceuticals Corporation | $410.75 | 2021-2022 | |
| Incyte Corporation | $410.44 | 2021-2024 | Jakafi, Pemazyre, Monjuvi |
| Eisai INC. | $406.11 | 2022-2024 | |
| Daiichi Sankyo INC. | $252.58 | 2021-2024 | Enhertu |
| Amgen INC. | $249.78 | 2021-2025 | Nplate, Xgeva, Vectibix |
| Seagen INC. | $241.76 | 2022-2023 | Adcetris, Tivdak |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $237.23 | 2021-2023 | Braftovi, Mektovi, Lorbrena |
| Gilead Sciences, INC. | $211.89 | 2021-2024 | Trodelvy |
| Beigene USA, INC. | $197.19 | 2022-2024 | Brukinsa |
| Astellas Pharma US INC | $151.50 | 2021-2022 | |
| Morphosys, US INC. | $147.37 | 2021-2023 | Monjuvi |
| Regeneron Healthcare Solutions, INC. | $138.08 | 2023 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $115.78 | 2022-2023 | Ninlaro, Fruzaqla |
| Lilly USA, LLC | $109.02 | 2021-2024 | Verzenio, Jaypirca, Retevmo |
| Bayer Healthcare Pharmaceuticals INC. | $107.46 | 2021-2023 | |
| Stemline Therapeutics INC. | $106.12 | 2023 | Orserdu, Elzonris |
| Puma Biotechnology, INC. | $95.34 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.42 | 2021-2023 | Gilotrif |
| Genentech USA, INC. | $87.29 | 2021-2022 | |
| Pharmaessentia USA Corporation | $85.00 | 2022-2024 | Besremi |
| Blueprint Medicines Corporation | $81.40 | 2021-2024 | Ayvakit |
| Coherus Oncology, INC. | $67.25 | 2022-2024 | |
| Genzyme Corporation | $58.87 | 2021-2023 | |
| Genmab U.S., INC. | $51.60 | 2023 | Epkinly |
| Ipsen Biopharmaceuticals, INC | $48.51 | 2021 | |
| Organon LLC | $48.10 | 2021-2022 | |
| Glaxosmithkline, LLC. | $44.20 | 2024 | Ojjaara |
| Emd Serono, INC. | $43.74 | 2021 | |
| Servier Pharmaceuticals LLC | $43.08 | 2022 | |
| Rigel Pharmaceuticals, INC. | $34.95 | 2022-2023 | Tavalisse, Rezlidhia |
| Deciphera Pharmaceuticals INC. | $26.88 | 2023 | Qinlock |
| Alexion Pharmaceuticals, INC. | $25.68 | 2024 | Ultomiris |
| Ge Healthcare | $25.21 | 2022 | |
| Agios Pharmaceuticals, INC. | $24.83 | 2023 | Pyrukynd |
| Genentech, INC. | $23.62 | 2023 | Columvi, Lunsumio |
| Karyopharm Therapeutics INC. | $23.33 | 2021 | |
| Adc Therapeutics America, INC. | $21.16 | 2023 | |
| Aveo Pharmaceuticals, INC. | $21.05 | 2023 | Fotivda |
| Recordati_rare_diseases_inc. | $20.69 | 2023 | Sylvant |
| Kyowa Kirin, INC. | $19.97 | 2024 | Poteligeo |
| Dova Pharmaceuticals | $16.03 | 2021 | |
| Sobi, INC | $14.80 | 2024 | |
| Mirati Therapeutics, INC. | $14.16 | 2023 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alpa Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.